FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4377983910> ?p ?o ?g. }

• W4377983910 abstract "Abstract Funding Acknowledgements Type of funding sources: Private company. Main funding source(s): Daiichi Sankyo (China) Holdings Co., Ltd, Shanghai, China. Background The effectiveness and safety of non-vitamin K antagonist oral anticoagulants (NOACs) edoxaban for the treatment of patients with non-valvular atrial fibrillation (NVAF) have been investigated globally. Data from mainland China, however, is scarce. Purpose To report baseline characteristics of unselected NVAF patients receiving edoxaban in routine clinical practice. Methods ETNA-AF-China is a multi-center, prospective, observational study designed to evaluate effectiveness and safety of edoxaban for stroke preventions in 89 sites across mainland China with 2-year follow-up. Enrollment started on February 2021 and ended on October 2022. Patients having history of NVAF, prescribed edoxaban, and providing written informed consent were eligible. This descriptive analysis of the baselines data is based on a snapshot from November 2022. Results A total of 5,000 patients were enrolled and data of 4749 patients with full edoxaban treatment information at baseline were analyzed (60 mg: 2559, 30 mg: 2190). Overall, mean (SD) patient age was 70.2 (9.55) years, with 1660 (35.0 %) patients ≥ 75 years. Male patients constituted 57.0 %. The average calculated creatinine clearance rate, CHA2DS2-VASc scores and HAS-BLED scores were 71.3 (27.8) mL/min, 2.88 (1.41) and 1.83 (1.04), respectively. Patients with perceived frailty, history of stroke, history of bleeding comprised 6.46 %, 8.78 %, 2.21% of the overall population, respectively (Table). The majority of patients (79.0 %) received recommended dose according to label criteria, with similar percentages observed among economic regions (East, 81.5 %; Northeast, 78.4 %; Middle, 76.0 %; West, 76.8 %). A numerically larger percentage of patients receiving non-recommended 30 mg were categorised as high risk for either stroke or bleeding (presence of prior stroke, prior major bleeding or prior ICH, or a CHA2DS2-VASc score ≥ 4; 34.1 % vs 25.6 %), frail assessed by physician (10.6 % vs 3.3 %), and had stage 3 chronic renal disease (58.8 % vs 39.4 %) compared with patients receiving recommended 60 mg. Those prescribed a non-recommended 60 mg vs those with recommended 30 mg were less likely to be considered stroke or bleeding high risk (40.2 % vs 46.8 %), and advanced renal disease (≥ stage 4, 10.7% vs 13.8 %) (Figure). Conclusion In this real-world study, edoxaban was predominantly prescribed with elder NVAF patients, on dose of 60 mg. Most of Chinese patients adhered to edoxaban approved label and the deviation from dose recommendation appears to be influenced by physician’s consideration of patient’s characteristics (such as stroke or bleeding high risk). More data profiles of ETNA-AF-China concerning effectiveness and safety study are collecting at the follow-up period." @default.
• W4377983910 created "2023-05-25" @default.
• W4377983910 creator A5000239300 @default.
• W4377983910 creator A5012356817 @default.
• W4377983910 creator A5014845109 @default.
• W4377983910 creator A5024971086 @default.
• W4377983910 creator A5025461362 @default.
• W4377983910 creator A5027958721 @default.
• W4377983910 creator A5033541840 @default.
• W4377983910 creator A5043343509 @default.
• W4377983910 creator A5050229781 @default.
• W4377983910 creator A5052435380 @default.
• W4377983910 creator A5053278238 @default.
• W4377983910 creator A5055041242 @default.
• W4377983910 creator A5064785596 @default.
• W4377983910 creator A5074552054 @default.
• W4377983910 creator A5086433594 @default.
• W4377983910 date "2023-05-24" @default.
• W4377983910 modified "2023-09-27" @default.
• W4377983910 title "Baseline characteristics of edoxaban treatment in routine clinical practice for patients with non-valvular atrial fibrillation in China (ETNA-AF-China)" @default.
• W4377983910 doi "https://doi.org/10.1093/europace/euad122.207" @default.
• W4377983910 hasPublicationYear "2023" @default.
• W4377983910 type Work @default.
• W4377983910 citedByCount "0" @default.
• W4377983910 crossrefType "journal-article" @default.
• W4377983910 hasAuthorship W4377983910A5000239300 @default.
• W4377983910 hasAuthorship W4377983910A5012356817 @default.
• W4377983910 hasAuthorship W4377983910A5014845109 @default.
• W4377983910 hasAuthorship W4377983910A5024971086 @default.
• W4377983910 hasAuthorship W4377983910A5025461362 @default.
• W4377983910 hasAuthorship W4377983910A5027958721 @default.
• W4377983910 hasAuthorship W4377983910A5033541840 @default.
• W4377983910 hasAuthorship W4377983910A5043343509 @default.
• W4377983910 hasAuthorship W4377983910A5050229781 @default.
• W4377983910 hasAuthorship W4377983910A5052435380 @default.
• W4377983910 hasAuthorship W4377983910A5053278238 @default.
• W4377983910 hasAuthorship W4377983910A5055041242 @default.
• W4377983910 hasAuthorship W4377983910A5064785596 @default.
• W4377983910 hasAuthorship W4377983910A5074552054 @default.
• W4377983910 hasAuthorship W4377983910A5086433594 @default.
• W4377983910 hasBestOaLocation W43779839101 @default.
• W4377983910 hasConcept C126322002 @default.
• W4377983910 hasConcept C127413603 @default.
• W4377983910 hasConcept C194828623 @default.
• W4377983910 hasConcept C23131810 @default.
• W4377983910 hasConcept C2776301958 @default.
• W4377983910 hasConcept C2778810321 @default.
• W4377983910 hasConcept C2779161974 @default.
• W4377983910 hasConcept C2780290652 @default.
• W4377983910 hasConcept C2780645631 @default.
• W4377983910 hasConcept C2908647359 @default.
• W4377983910 hasConcept C71924100 @default.
• W4377983910 hasConcept C78519656 @default.
• W4377983910 hasConcept C99454951 @default.
• W4377983910 hasConceptScore W4377983910C126322002 @default.
• W4377983910 hasConceptScore W4377983910C127413603 @default.
• W4377983910 hasConceptScore W4377983910C194828623 @default.
• W4377983910 hasConceptScore W4377983910C23131810 @default.
• W4377983910 hasConceptScore W4377983910C2776301958 @default.
• W4377983910 hasConceptScore W4377983910C2778810321 @default.
• W4377983910 hasConceptScore W4377983910C2779161974 @default.
• W4377983910 hasConceptScore W4377983910C2780290652 @default.
• W4377983910 hasConceptScore W4377983910C2780645631 @default.
• W4377983910 hasConceptScore W4377983910C2908647359 @default.
• W4377983910 hasConceptScore W4377983910C71924100 @default.
• W4377983910 hasConceptScore W4377983910C78519656 @default.
• W4377983910 hasConceptScore W4377983910C99454951 @default.
• W4377983910 hasIssue "Supplement_1" @default.
• W4377983910 hasLocation W43779839101 @default.
• W4377983910 hasLocation W43779839102 @default.
• W4377983910 hasOpenAccess W4377983910 @default.
• W4377983910 hasPrimaryLocation W43779839101 @default.
• W4377983910 hasRelatedWork W1967841144 @default.
• W4377983910 hasRelatedWork W2039688335 @default.
• W4377983910 hasRelatedWork W2062848816 @default.
• W4377983910 hasRelatedWork W2126858523 @default.
• W4377983910 hasRelatedWork W2319489406 @default.
• W4377983910 hasRelatedWork W2366640585 @default.
• W4377983910 hasRelatedWork W2409400224 @default.
• W4377983910 hasRelatedWork W3132289493 @default.
• W4377983910 hasRelatedWork W4200210752 @default.
• W4377983910 hasRelatedWork W4386151186 @default.
• W4377983910 hasVolume "25" @default.
• W4377983910 isParatext "false" @default.
• W4377983910 isRetracted "false" @default.
• W4377983910 workType "article" @default.